Daclizumab (Zenapax) News and Research

RSS

Daclizumab is a monoclonal antibody that is being studied for treatment of adult T-cell leukemia. Also called dacliximab. Monoclonal antibodies are laboratory-produced substances that can locate and bind to cancer cells.

Renal transplantation in 1-5 year olds

Garcia, et al reported their experience with renal transplantation in 38 children (40 transplant), ages 1-5 years over a 16 year period.

26 Apr 2007

PDL BioPharma's European patent claims upheld

PDL BioPharma has announced that the Opposition Division of the European Patent Office decided at an oral proceeding to uphold claims in the company's European Patent No. 0 451 216 ('216 patent) that are virtually identical to the claims remitted to the Opposition Division by the Board of Appeal.

25 Apr 2007

New insights into how anti-rejection drug daclizumab (Zenapax) helps MS patients

A research team led by the University of Cincinnati's Bibiana Bielekova, MD, report new insights into the role of the MS drug daclizumab (Zenapax) in the Proceedings of the National Academy of Sciences.

11 Apr 2006

Daclizumab effective at reducing organ rejection and risk of infection in heart transplant patients

A new study shows that a drug, called daclizumab, is effective at reducing organ rejection and risk of infection in heart transplant patients. The multi-center study by cardiologists from the United States, Sweden, Germany and Canada will be published in the June 30 issue of The New England Journal of Medicine.

30 Jun 2005

Trial shows Daclizumab therapy improves multiple sclerosis outcome

A small clinical trial of patients with multiple sclerosis (MS) who did not respond to interferon alone found that adding the human antibody daclizumab improved patient outcome. Patients who received the combined therapy had a 78 percent reduction in new brain lesions and a 70 percent reduction in total lesions, along with other significant clinical improvements.

24 May 2004